Trader consensus on Polymarket tilts slightly toward "No" at 52% implied probability for Eli Lilly licensing Peptron's SmartDepot sustained-release platform by October 7, reflecting prolonged evaluation without a full commercial commitment despite a December 2025 extension to October 2026. Peptron's ultrasonic spray-drying technology, designed for long-acting peptide injectables like GLP-1s, remains in joint R&D testing on Lilly's candidates, but skepticism stems from Lilly's June 2025 Camurus partnership for similar depot tech and recent pivots to oral obesity drugs such as Foundayo. This balance persists amid no fresh data readouts or announcements in the past month. Key catalysts include in vivo evaluation results or partnership updates ahead of the deadline, potentially swaying odds in Q3 earnings calls.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
ใหม่
ใหม่
Oct 7, 2026
ใหม่
ใหม่
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Trader consensus on Polymarket tilts slightly toward "No" at 52% implied probability for Eli Lilly licensing Peptron's SmartDepot sustained-release platform by October 7, reflecting prolonged evaluation without a full commercial commitment despite a December 2025 extension to October 2026. Peptron's ultrasonic spray-drying technology, designed for long-acting peptide injectables like GLP-1s, remains in joint R&D testing on Lilly's candidates, but skepticism stems from Lilly's June 2025 Camurus partnership for similar depot tech and recent pivots to oral obesity drugs such as Foundayo. This balance persists amid no fresh data readouts or announcements in the past month. Key catalysts include in vivo evaluation results or partnership updates ahead of the deadline, potentially swaying odds in Q3 earnings calls.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ตลาดเปิดเมื่อ: May 5, 2026, 8:02 PM ET
ปริมาณการซื้อขาย
$8,097วันสิ้นสุด
Oct 7, 2026ตลาดเปิดเมื่อ
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Trader consensus on Polymarket tilts slightly toward "No" at 52% implied probability for Eli Lilly licensing Peptron's SmartDepot sustained-release platform by October 7, reflecting prolonged evaluation without a full commercial commitment despite a December 2025 extension to October 2026. Peptron's ultrasonic spray-drying technology, designed for long-acting peptide injectables like GLP-1s, remains in joint R&D testing on Lilly's candidates, but skepticism stems from Lilly's June 2025 Camurus partnership for similar depot tech and recent pivots to oral obesity drugs such as Foundayo. This balance persists amid no fresh data readouts or announcements in the past month. Key catalysts include in vivo evaluation results or partnership updates ahead of the deadline, potentially swaying odds in Q3 earnings calls.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ปริมาณการซื้อขาย
$8,097วันสิ้นสุด
Oct 7, 2026ตลาดเปิดเมื่อ
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Trader consensus on Polymarket tilts slightly toward "No" at 52% implied probability for Eli Lilly licensing Peptron's SmartDepot sustained-release platform by October 7, reflecting prolonged evaluation without a full commercial commitment despite a December 2025 extension to October 2026. Peptron's ultrasonic spray-drying technology, designed for long-acting peptide injectables like GLP-1s, remains in joint R&D testing on Lilly's candidates, but skepticism stems from Lilly's June 2025 Camurus partnership for similar depot tech and recent pivots to oral obesity drugs such as Foundayo. This balance persists amid no fresh data readouts or announcements in the past month. Key catalysts include in vivo evaluation results or partnership updates ahead of the deadline, potentially swaying odds in Q3 earnings calls.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย